Zdrowie i gospodarka · 13/06/2025

FDA Classifies Clinical Mass Spectrometry Microorganism Identification and Differentiation System into Class II Special Controls

The FDA has classified the clinical mass spectrometry microorganism identification and differentiation system into Class II special controls, aiming to ensure safety and effectiveness while reducing regulatory burdens and enhancing patient access to innovative devices.